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Abstract: Cyclooxygenase-2 (COX-2) is the inducible form of
the enzyme involved in the first steps of the prostaglandins and
thromboxane synthesis. COX-2 up-regulation is demonstrated
in tumors where it can modulate tumoral progression, metas-
tasis, multidrug resistance, and angiogenesis. Experimental data
suggest a possible therapeutic use of the COX-inhibitors
nonsteroidal antiinflammatory drugs (NSAIDs). NSAIDs can
block tumor growth through many mechanisms, especially
through antiangiogenic and proapoptotic effects. Moreover,
NSAIDs can also improve the efficacy of radiotherapy, che-
motherapy, and hormonal therapy. This study reviews the COX-2
expression as evaluated through immunohistochemistry and real
time polymerase chain reaction (RT-PCR) in 23 meningiomas [14
World Health Organization (WHO) grade I; 5 WHO grade II; 3
WHO grade III; 1 oncocytic meningioma]. At immunohisto-
chemistry all the lesions but 4 (83%) were COX-2 positive. At
RT-PCR 9 meningiomas, 8 WHO grade I and 1 WHO grade II,
showed a COX-2 expression greater than the reference value
(average expression of all meningiomas that we studied). The
association between tumor grade and immunohistochemical or
RT-PCR COX-2 expression was not significant (P=0.427 and
P=0.251, respectively). In conclusion, even if further studies on
larger series are necessary, the common COX-2 overexpression in
meningiomas may suggest considering the COX-2 inhibitors,
alone or in combination with radiotherapy, a potential area of
therapeutic intervention in some selected meningiomas.
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Cyclooxygenase (COX) is a membrane-bound enzymeinvolved in the first steps of the prostaglandins (PG)
and thromboxane (TX) synthesis from arachidonic acid.
There are 2 principal COX isoforms designated as COX-1
and COX-2, encoded by separate genes localized on
chromosome 9q and chromosome 1q. Although COX-1,
a 66 kd protein, is constitutively expressed almost
ubiquitously in mammalian tissues, where it controls
several normal physiological functions (ie, maintenance
of the gastric mucosa, regulation of renal blood flow,
platelet aggregation), COX-2, a 70 kd protein sharing
61% sequence identity with COX-1, is induced by several
mitogenic and inflammatory stimuli.1–9
Lately, another COX isoform, known as COX-3,
has been recognized. It derives through the retention of a
highly structured G+C-rich intron 1 of the COX-1 gene
and it is especially abundant in the cerebral cortex and in
the heart.10,11
COX-2 plays a critical role in the development of
neoplasms in various, although not completely clear, ways.
Our knowledge on the role of COX-2 in the development of
cancer is mainly derived from studies on colon carcinoma.
Nevertheless, numerous researches have documented that
COX-2 is also overexpressed in different premalignant and
malignant conditions where it can stimulate gene transcrip-
tion, tumoral growth, angiogenesis, metastasis, and im-
munosuppression, inhibit apoptosis, and cause resistance to
chemotherapy through P-glicoprotein-170 overexpression.
COX-2 overexpression may be a consequence of increased
transcription and/or enhanced mRNA stability.3,12–20
Experimental data suggest a possible therapeutic
use of the COX-inhibitors nonsteroidal antiinflammatory
drugs (NSAIDs). NSAIDs can block tumor growth
through many mechanisms, especially through antiangio-
genic and proapoptotic effects. Moreover, NSAIDs can
also improve the efficacy of radiotherapy, chemotherapy,
and hormonal therapy.21,22
However, conventional NSAIDs (ie, aspirin, indo-
methacin, ibuprofen, etc), inhibiting both COX-2 and
COX-1, elicit the suppression of PG production in the
gastrointestinal and renal systems with the consequent
possible damage of the gastric mucosa and of the renal
and platelet functions. For this reason, there is a growing
interest in new classes of NSAIDs that selectively inhibit
COX-2. Nevertheless, some recent data seem to indicate
the propensity of COX-2 inhibitors to trigger throm-
bo-embolic adverse events because of the inhibition ofCopyright r 2007 by Lippincott Williams & Wilkins
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PGI2 synthesis (PGI2 mainly derives from endothelial
COX-2 and causes vasodilatation, inhibition of platelet
aggregation, and vascular smooth-muscle proliferation)
unopposed by the inhibition of the TXA2 synthesis
(TXA2 mainly derives from COX-1 and determines
vasoconstriction, platelet aggregation, and vascular pro-
liferation).23,24
COX-2 is frequently expressed in the brain during
different pathologic conditions. There are numerous data
showing the presence of COX-2 in the glioma-affected
brain and indicating the therapeutic effectiveness of COX
inhibitors in the gliomas.2,3,15,19,20,25–30
On the contrary, there is little reported information
about the expression of COX-2 in meningiomas.31–34
In 2001, Matsuo et al31 noted that all meningiomas
that they immunohistochemically examined were COX-2
positive; in 2003, Lin et al32 demonstrated that menin-
giomas with a more aggressive phenotype [as assessed by
a modified 1993 World Health Organization (WHO)
classification system] were associated with increasingly
immunohistochemical COX-2 expression.
In the present work, we studied COX-2 expression
through immunohistochemistry and real time polymerase
chain reaction (RT-PCR) in a group of 23 meningiomas
and we evaluated its possible correlation with tumor
grade.
PATIENTS AND METHODS
Patients
Tissue specimens were obtained from 23 patients
affected by meningiomas surgically treated at the Neuro-
surgical Service (Careggi Hospital, Florence, Italy) in
which fresh tumoral tissue was available for RT-PCR.
Eighteen (78%) were from women and 5 (22%) were from
men. The average age at the time of the surgery was 52
years (range 29 to 76 years).
Twenty-two (96%) meningiomas were intracranial
(1 of which was intraventricular) and the one remaining
(4%) meningioma was spinal; 3 meningiomas (9%) were
relapsed tumors and 2 meningiomas (9%) were multiple
(Table 1).
RT-PCR
From each fresh surgical specimen, we selected a
fragment macroscopically representative of the lesion.
Successively, we cut each fragment in half: from one half,
several 5-mm frozen sections stained with hematoxylin
and eosin were obtained to verify the adequacy of the
specimens selected for RT-PCR (presence of pathologic
tissue only); the other half was immersed in RNA later
(QIAGEN, Valencia, CA), kept overnight at +41C and
finally stored at  801C until analyzed.
The thawed specimens were cut in small pieces and
homogenized. After proteinase K digestion (250 mg/mL
for 1 hour at 371C), total RNA was isolated with 6100
Nucleic Acid PrepStation (manufacturer’s protocol).
Total RNA (500 ng) was subjected to reverse transcrip-
tion of cDNA using a High Capacity cDNA Archive Kit
(Applied Biosystems, Foster City, CA) (manufacturer’s
protocol). Real time quantitative PCR was performed on
an ABI PRISM 7000 Sequence Detector System (Applied
Biosystems). PCR products for COX-2 were detected
using gene-specific primers and probes labeled with
reporter day FAM (Assay on Demand, Applied Biosys-
tems). Human glyceroaldehyde phosphate dehydrogenase
(gAPDH) was used as endogenous control gene for
normalization.
TABLE 1. Clinical Data, Histopathology, and Immunohistochemical and RT-PCR Results
Clinical Data Histopathology
Case Patient Sex/Age Tumor WHO Grade Histotype ICC PCR
1 Female/38 Intracranial Primary Multiple I Fibrous Diffuse ++  1.01
2 Female/66 Intracranial Primary Single I Fibrous Diffuse ++  1.03
3 Female/46 Spinal Primary Single I Fibrous Diffuse + 2.06
4 Male/29 Intracranial Primary Single I Fibrous Diffuse ++ 0.78
5 Female/41 Intracranial Primary Single I Fibrous Negative  0.76
6 Female/43 Intracranial Primary Multiple I Fibrous Focal + 0.89
7 Female/35 Intracranial Primary Single I Fibrous Diffuse ++ 0.90
8 Female/68 Intracranial Primary Single I Fibrous Negative  0.71
9 Male/74 Intracranial Primary Single I Fibrous Diffuse ++ 0.39
10 Female/51 Intracranial Primary Single I Meningothelial Diffuse ++ 1.40
11 Female/32 Intracranial Primary Single I Meningothelial Diffuse ++ 1.81
12 Female/60 Intracranial Primary Single I Meningothelial Negative  0.88
13 Female/66 Intracranial Primary Single I Psammomatous Focal +  0.45
14 Male/64 Intracranial Primary Single I Angiomatous Diffuse ++ 2.50
15 Female/41 Intracranial Primary Single II Atypical Focal +  0.83
16 Female/76 Intraventricular Primary Single II Atypical Diffuse + 0.14
17 Female/57 Intracranial Primary Single II Atypical Diffuse ++  0.29
18 Female/66 Intracranial Primary Single II Atypical Negative  1.07
19 Female/44 Intracranial Relapse Single II Chordoid Diffuse +  1.58
20 Male/69 Intracranial Primary Single III Anaplastic Diffuse ++  0.43
21 Male/37 Intracranial Relapse Single III Anaplastic Diffuse ++  0.48
22 Female/63 Intracranial Relapse Single III Anaplastic Diffuse +  0.92
23 Female/39 Intracranial Primary Single — Oncocytic Focal +  0.43
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PCR reactions were carried out in 96-well plates
with 20 mL per well using 1 TaqMan Universal PCR
MasterMix. After incubation for 2 minutes at 501C and
10 minutes at 951C, the reaction continued for 50 cycles at
951C for 15 seconds and 601C for 1 minute. The 2DDCt
method described by Livak et al35 was used to calculate
fold expression levels relative to the average value of all
the meningiomas RNA specimens (the calibrator). We
chose the average expression of all the meningiomas as
the reference value to emphasize the strong difference of
expression.
Histopathology and Immunohistochemistry
After drawing off the small samples for RT-PCR,
the remaining tissues were routinely fixed in 10% buffered
formalin and embedded in paraffin.
Five-mm thick sections were stained with hemato-
xylin and eosin for morphological evaluation. The
diagnostic criteria we used were those indicated by the
most recently revised WHO classification of tumors of the
nervous system36.
Further 5-mm thick sections of the most representa-
tive specimen of each case were mounted on electrostatic
slides for the immunohistochemical evaluation of COX-2
expression (clone COX 229; Zymed Laboratories, San
Francisco, CA). Paraffin and antigen retrieval were
performed by immersing the slides in boiling Tris-
EDTA-Citrate ready-to-use buffer (W-cap-‘‘wax cap-
ture’’-Tris-EDTA-Citrate buffer pH 8, BIO-OPTICA)
for 20 minutes. Endogenous peroxidase activity was
blocked with 3% hydrogen peroxide in distilled water
for 10 minutes. The primary antibody was used at 1:50
dilution at room temperature for 1 hour, followed by
incubation with peroxidase conjugate polymer (Chem-
mate Dako Envision Detection Kit Peroxidase DAB
rabbit-mouse) for 30 minutes. The reaction products were
visualized with diaminobenzidine (Chemmate DAB
Chromogen Dako) for 5 minutes. The nuclei were
counterstained with hematoxylin. The following proce-
dures were used as negative controls:
 a nonimmune serum in place of the primary antibody;
and
 omitting the primary antibody.
An ascertained COX-2-positive colon adenocarci-
noma was used as positive control.
Cytoplasmic COX-2 expression was considered as
negative when it was less than 25% or absent, as focal
when it was present in more than 25% and less than 50%
of the neoplastic cells, and as diffuse when it was present
in 50% or more of the neoplastic cells. Furthermore, we
graded immunocoloration as + (weak) or ++ (intense)
on the basis of intensity of staining.
Statistical Analysis
The shift of expression level of COX-2 as estimated
through immunohistochemistry and relative RT-PCR
was calculated according to the Wilcoxon Mann-Whitney
P value r0.05 was considered to be statistically
significant.
RESULTS
Fourteen (61%) lesions were WHO grade I menin-
giomas (9 fibrous, 3 meningothelial, 1 psammomatous,
1 angiomatous); 5 (22%) were WHO grade II meningiomas
(4 atypical, 1 chordoid); 3 (13%) were anaplastic meningio-
mas; and the one remaining (4%) was oncocytic meningio-
ma, a novel uncategorized rare variant showing oncocytic
differentiation (wide granular cytoplasm full of numerous
swollen mitochondria) and uncertain prognosis (Fig. 1).
At immunohistochemistry all the lesions but 4
(2 fibrous, 1 meningothelial, 1 atypical) (83%) were
COX-2 positive. Eleven positive meningiomas were
scored as diffuse ++ (5 fibrous, 2 meningothelial,
1 angiomatous, 1 atypical, 2 anaplastic), 4 as diffuse +
(1 fibrous, 1 atypical, 1 chordoid, 1 anaplastic), and 4 as
focal + (1 fibrous, 1 psammomatous, 1 atypical, 1
oncocytic). Endothelial cells, in either positive or negative
meningiomas, were COX-2 positive (Fig. 2).
There were no significant differences in immunohis-
tochemical expression of COX-2 related to histological
grade (P=0.427).
RNA extraction was successful in all cases. The
COX-2 expression of each meningioma was compared
with the average value of expression (reference value) of
the entire group of meningiomas (23 cases). Nine
meningiomas (39%), 8 WHO I (5 fibrous, 2 meningothe-
lial, and 1 angiomatous) and 1 WHO II, showed COX-2
expression greater than the average of the entire group of
meningiomas. Angiomatous meningiomas had the highest
COX-2 expression (Figs. 3, 4).
There were no significant differences in RT-PCR
expression of COX-2 related to histologic grade
(P=0.251).
When comparing the RT-PCR results with the
immunohistochemical results, there was significant dis-
cordance in 5 out of 23 (22%) meningiomas. Precisely,
FIGURE 1. Oncocytic meningioma: the lesion is composed of
sheets of rounded cells with wide granular eosinophilic
cytoplasm (inset).
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5 meningiomas (2 fibrous, 1 atypical, 2 anaplastic) were
diffusely and intensely positive at immunohistochemistry
(diffuse ++ score) and showed low (less than the
reference value) COX-2 expression at RT-PCR. In the
remaining cases, the lesions were negative or weakly
positive at immunohistochemistry (diffuse + or focal +
score) and presented low (less than the reference value)
COX-2 expression at RT-PCR, whereas those showing
diffuse and intense (diffuse ++ score) COX-2 immuno-
reaction had high (more than the reference value) COX-2
expression at RT-PCR.
DISCUSSION
Meningiomas are frequent neoplasms (13% to 26%
of primary intracranial tumor) arising from the leptome-
ningeal covering of the brain and spinal cord. They
typically manifest in adult women. Although menin-
giomas are generally considered slow-growing, benign
tumors, their long-term prognosis may be tainted by
recurrences or by aggressive behavior (invasion of the
brain and adjacent bones).36,37
The morphology of meningiomas is highly poly-
morphic, with numerous classified subtypes (the most
FIGURE 2. Immunohistochemis-
try: meningothelial (right) and
angiomatous (left) positive menin-
giomas (neoplastic and endothe-
lial cells).
FIGURE 3. RT-PCR: the graph shows fluorescence signals accumulated at different PCR cycles.
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recent WHO scheme recognizes 13 variants), several
uncategorized histologic variants (ie, oncocytic meningio-
ma), and 3 histologic grades (WHO I; WHO II; WHO III)
depending upon the presence of histopathologic features
thought to predict unfavorable behavior (mitosis, in-
creased cellularity, small cells, macronucleoli, sheetlike
growth, necrosis, and sarcomatous, carcinomatous or
melanomalike appearance).36–38
In the majority of cases, chordoid and clear cell that
are equalized to atypical meningiomas, and rhabdoid and
papillary that are equalized to anaplastic meningiomas,
the histologic variant does not condition the prognosis.36
The clinical behavior of meningioma mainly de-
pends upon the extent of resection and histologic grade.
The overall recurrence rate of meningiomas is reported to
be approximately 20%, with higher rates for partially
excised meningiomas (30% to 40%), atypical meningio-
mas (38%), and malignant meningiomas (78%).36,37
The management of certain meningiomas such as
multiple and recurrent lesions, in which total resection is
difficult to obtain (ie, meningiomas of the skull base or
involving the dural venous sinuses), and those in patients
who are medically unsuitable for surgery, may be difficult.
If surgical excision, the cornerstone of treatment for all
types of meningiomas, is not possible, radiation therapy
is beneficial whereas stereotactic radiation, interstitial
brachytherapy, hormonal manipulation or chemotherapy
may represent therapeutic opportunities in some selected
patients.39–43
As indicated by numerous data concerning colon
carcinoma, NSAIDs may be considered interesting
therapeutic opportunities in the treatment of different
tumors. In fact, the demonstration that NSAIDs
significantly reduce the risk of insurgence of colorectal
tumors and the number of preexisting adenomas
in adenomatous familial syndrome-affected patients
suggested the possibility of an analogous role in
other tumors, and several reports have confirmed this
hypothesis.21,22,44–50
The possibility of a therapeutic use of NSAIDs in
meningiomas can be argued if COX-2 overexpression is
proved.
In accordance with Matsuo et al,31 we noted COX-2
overexpression in the majority of meningiomas. On the
other hand, contrary to the results obtained by Lin et al32
using a modified 1993 WHO grading system, increased
COX-2 expression was not detected in high-grade
meningiomas with respect to low-grade meningiomas.
Actually, Lin himself supposed that increased COX-2
expression in more malignant meningiomas could be
interpreted as an indicator of ischemia (COX-2 is elevated
around areas of necrosis and high-grade meningiomas
present necrosis more often than low-grade meningiomas)
rather than as a marker of malignancy. When evaluated
through RT-PCR, increased COX-2 expression may also
be related to vessel density of the lesion (endothelial cells
overexpress COX-2). Angiomatous meningiomas of our
series showed the highest COX-2 expression at RT-PCR.
The discordant results between immunohistochemi-
stry and RT-PCR could be explained by the modality of
COX-2 quantification (our reference value was the
average expression of all 23 meningiomas) or by the
fortuitous evaluation of areas with different levels of
COX-2 expression by one method with respect to
another.
In conclusion, we documented that meningiomas,
independent of tumor grade, commonly overexpress
COX-2. This result, even though further studies on larger
and homogeneous series are certainly necessary, could
suggest evaluating the possibility of utilization of
NSAIDs, alone or in combination with radiotherapy, in
the treatment of some selected meningiomas.
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FIGURE 4. Relative expression of
COX-2 in different types of me-
ningioma. The average value of all
the meningiomas RNA specimens
was used as a reference value;
cases 1 to 9: fibrous meningiomas;
cases 10 to 12: meningothelial
meningiomas; case 13: psammo-
matous meningioma; case 14:
angiomatous meningioma; cases
15 to 18: atypical meningiomas;
case 19: chordoid meningioma;
cases 20 to 22: anaplastic menin-
giomas; case 23: oncocytic me-
ningioma.
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